Join AAPP and other stakeholders in sharing your voice (using the provided toolkit) recommending the elimination of the DEA prohibition on the prescribing of methadone. The DOJ Anticompetitive Regulations Task Force is seeking comment by May 27 on regulations that prevent competition within the health care sector. Current regulation that limits dispensing of methadone for OUD to opioid treatment programs (OTP) is anticompetitive and severely restricts patient access to treatment. Fixing this regulation to allow practitioners to prescribe methadone for OUD that patients can pick up at a local pharmacy would greatly improve patient choice in addiction treatment – especially in cases where methadone is the most effective option for an individual.